Shorter Durations of Anti-HER2 Therapy for Patients with Early-Stage, HER2-Positive Breast Cancer: The Physician Perspective

Shorter Durations of Anti-HER2 Therapy for Patients with Early-Stage, HER2-Positive Breast Cancer: The Physician Perspective

Despite evidence from clinical trials showing the efficacy of shorter durations of therapy, most HER2-positive early breast cancer (EBC) patients receive a year of anti-HER2 therapy. A survey of Canadian oncologists was conducted online, with electronic data collection, and the analysis is reported...

Full description

Bibliographic Details
Main Authors: Michelle Bradbury, Marie-France Savard, Lisa Vandermeer, Lucas Clemons, Gregory Pond, John Hilton, Mark Clemons, Sharon McGee
Format: Article
Language:English
Published: MDPI AG 2023-12-01
Series:Current Oncology
Subjects:
breast cancer
HER2
trastuzumab
Online Access:https://www.mdpi.com/1718-7729/30/12/763

Similar Items

Similar Items